Patients with borderline resectable pancreatic cancer are at high risk of having positive surgical margins due to involvement of the tumor with adjacent vasculature. This article reviews the management of this subset of pancreatic cancer patients.
Methods
The authors review the current definitions of borderline resectable pancreatic cancer and how it is diagnosed and staged. The history, current approaches, and future directions in neoadjuvant therapy for borderline resectable pancreatic cancer are also reviewed with emphasis on various chemotherapy regimens that have been used. The application of intensity-modulated radiation therapy and image-guided radiation therapy that accounts for respiratory motion to targeting the gross tumor volume in the pancreas are discussed, and the promise of integrating targeted therapies in neoadjuvant treatment programs is highlighted.
Results
The use of neoadjuvant treatment programs that employ gemcitabine-based chemotherapy regimens followed by chemoradiation increases the likelihood of subsequent margin-negative resection in borderline resectable pancreatic cancer.
Conclusions
There has been progress in the imaging, staging, surgical technique, and the use of chemotherapy and chemoradiotherapy in the management of borderline resectable pancreatic cancer. Patients can benefit from multidisciplinary management at high-volume pancreatic cancer treatment centers.
References
1.
VaradhacharyG.R., TammE.P., AbbruzzeseJ.L.. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.Ann Surg Oncol.2006; 13(8): 1035–1046. Epub 2006 Jul 24.
NCCN practice guidelines for pancreatic cancer.Oncology (Williston Park).1997; 11(11A): 41–55.
4.
YendluriV., CentenoB., SpringettG.M.. Pancreatic cancer presenting as a Sister Mary Joseph's nodule: case report and update of the literature.Pancreas.2007; 34(1): 161–164.
5.
MehtaV.K., FisherG., FordJ.A.. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas.J Gastrointest Surg.2001; 5(1): 27–35.
6.
VallsC., AndíaE., SanchezA.. Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery.AJR Am J Roentgenol.2002; 178(4): 821–826.
7.
LegmannP., VignauxO., DoussetB.. Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography.AJR Am J Roentgenol.1998; 170(5): 1315–1322.
8.
DeWittJ., DevereauxB., ChriswellM.. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer.Ann Intern Med.2004; 141(10): 753–763.
9.
MichlP., PaulsS., GressT.M.. Evidence-based diagnosis and staging of pancreatic cancer.Best Pract Res Clin Gastroenterol.2006; 20(2): 227–251.
10.
FarmaJ.M., MelisM., SantillanA.. Positron emission tomography/computed tomography fusion scans enhances preoperative treatment planning in patients with pancreatic cancer. In: Proceedings from the 61st Annual Society of Surgical Oncology Meeting; March 13-16, 2008; Chicago, IL. Abstract 10.
11.
FarmaJ.M., SantillanA.A., MelisM.. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms.Ann Surg Oncol.2008 Jun 13. Epub ahead of print.
12.
LuD.S., ReberH.A., KrasnyR.M.. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT.AJR Am J Roentgenol.1997; 168(6): 1439–1443.
HoughT.J., RaptopoulosV., SiewertB.. Teardrop superior mesenteric vein: CT sign for unresectable carcinoma of the pancreas.AJR Am J Roentgenol.1999; 173(6): 1509–1512.
15.
PilepichM.V., MillerH.H.. Preoperative irradiation in carcinoma of the pancreas.Cancer.1980; 46(9): 1945–1949.
16.
MoertelC.G., FrytakS., HahnR.G.. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The Gastrointestinal Tumor Study Group.Cancer.1981; 48(8): 1705–1710.
17.
RoldanG.E., GundersonL.L., NagorneyD.M.. External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer.Cancer.1988; 61(6): 1110–1116.
18.
RabenA., MychalczakB., BrennanM.F.. Feasibility study of the treatment of primary unresectable carcinoma of the pancreas with 103Pd brachytherapy.Int J Radiat Oncol Biol Phys.1996; 35(2): 351–356.
19.
EvansD.B., RichT.A., ByrdD.R.. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.Arch Surg.1992; 127(11): 1335–1339.
HoffmanJ.P., WeeseJ.L., SolinL.J.. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas.Am J Surg.1995; 169(1): 71–77; discussion 77-78.
22.
HoffmanJ.P., LipsitzS., PisanskyT.. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study.J Clin Oncol.1998; 16(1): 317–323.
23.
SnadyH., BrucknerH., CoopermanA.. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma: an outcomes trial.Cancer.2000; 89(2): 314–327.
24.
MassuccoP., CapussottiL., MagninoA.. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.Ann Surg Oncol.2006; 13(9): 1201–1208. Epub 2006 Sep 6.
25.
WhiteR.R., HurwitzH.I., MorseM.A.. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas.Ann Surg Oncol.2001; 8(10): 758–765.
26.
ChengT.Y., ShethK., WhiteR.R.. Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy.Ann Surg Oncol.2006; 13(1): 66–74. Epub 2006 Jan 1.
27.
BurrisHA3rd, MooreM.J., AndersenJ.. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.J Clin Oncol.1997; 15(6): 2403–2413.
28.
LawrenceT.S., ChangE.Y., HahnT.M.. Radiosensitization of pancreatic cancer cells by 2’,2′-difluoro-2′-deoxycytidine.Int J Radiat Oncol Biol Phys.1996; 34(4): 867–872.
29.
ShewachD.S., LawrenceT.S.. Gemcitabine and radiosensitization in human tumor cells.Invest New Drugs.1996; 14(3): 257–263.
30.
McGinnC.J., ZalupskiM.M.. Radiation therapy with once-weekly gemcitabine in pancreatic cancer: current status of clinical trials.Int J Radiat Oncol Biol Phys.2003; 56(4 suppl): 10–15.
31.
CraneC.H., AbbruzzeseJ.L., EvansD.B.. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?Int J Radiat Oncol Biol Phys.2002; 52(5): 1293–1302.
32.
McGinnC.J., ZalupskiM.M., ShureiqiI.. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.J Clin Oncol.2001; 19(22): 4202–4208.
33.
WilkowskiR., ThomaM., SchauerR.. Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer.World J Surg.2004; 28(10): 1011–1018. Epub 2004 Sep 29.
34.
SafranH., DipetrilloT., IannittiD.. Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a phase I trial.Int J Radiat Oncol Biol Phys.2002; 54(1): 137–141.
RiallT.S., CameronJ.L., LillemoeK.D.. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. Part 3: update on 5-year survival.J Gastrointest Surg.2005; 9(9): 1191–1204; discussion 1204-1206.
37.
BrownM.W., NingH., AroraB.. A dosimetric analysis of dose escalation using two intensity-modulated radiation therapy techniques in locally advanced pancreatic carcinoma.Int J Radiat Oncol Biol Phys.2006; 65(1): 274–283.
38.
BryanP.J., CustarS., HaagaJ.R.. Respiratory movement of the pancreas: an ultrasonic study.J Ultrasound Med.1984; 3(7): 317–320.
39.
BusselsB., GoethalsL., FeronM.. Respiration-induced movement of the upper abdominal organs: a pitfall for the three-dimensional conformal radiation treatment of pancreatic cancer.Radiother Oncol.2003; 68(1): 69–74.
40.
BhasinD.K., RanaS.S., JahagirdarS.. Does the pancreas move with respiration?J Gastroenterol Hepatol.2006; 21(9): 1424–1427.
41.
GiergaD.P., BrewerJ., SharpG.C.. The correlation between internal and external markers for abdominal tumors: implications for respiratory gating.Int J Radiat Oncol Biol Phys.2005; 61(5): 1551–1558. Erratum in: Int J Radiat Oncol Biol Phys. 2005;62(4): 1257.
42.
ShiratoH., ShimizuS., KuniedaT.. Physical aspects of a realtime tumor-tracking system for gated radiotherapy.Int J Radiat Oncol Biol Phys.2000; 48(4): 1187–1195.
43.
EcclesC., BrockK.K., BissonnetteJ.P.. Reproducibility of liver position using active breathing coordinator for liver cancer radiotherapy.Int J Radiat Oncol Biol Phys.2006; 64(3): 751–759.
44.
KiniV.R., VedamS.S., KeallP.J.. Patient training in respiratory-gated radiotherapy.Med Dosim.2003; 28(1): 7–11.
45.
KoongA.C., LeQ.T., HoA.. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer.Int J Radiat Oncol Biol Phys.2004; 58(4): 1017–1021.
46.
KoongA.C., ChristoffersonE., LeQ.T.. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.Int J Radiat Oncol Biol Phys.2005; 63(2): 320–323.
47.
KrishnanS., RanaV., JanjanN.A.. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.Cancer.2007; 110(1): 47–55.
48.
FogelmanD.R., SchreibmanS., ShermanW.. Neoadjuvant GTX and radiation for unresectable pancreatic cancer: a prospective phase II trial. In: Proceedings from the 4th Annual Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, FL. Abstract 143.
49.
FineR.L., FogelmanD.R., SchreibmanS.M.. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.Cancer Chemother Pharmacol.2008; 61(1): 167–175. Epub 2007 Apr 18.
50.
LandryJ., CatalanoP., HoffmanJ.. ECOG 1200: a randomized phase II trial of gemcitabine plus radiotherapy vs gemcitabine, 5-fluorouracil and cisplatin followed by radiotherapy and 5-fluorouracil in patients with locally advanced, potentially resectable pancreatic adenocarcinoma.Int J Radiat Oncol Biol Phys.2006; 66(3): S272. Abstract 2111.
51.
HeinrichS., PestalozziB.C., SchäferM.. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head.J Clin Oncol.2008; 26(15): 2526–2531.
52.
MooreM.J., GoldsteinD., HammJ.. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.J Clin Oncol.2007; 25(15): 1960–1966. Epub 2007 Apr 23.
53.
BonnerJ.A., HarariP.M., GiraltJ.. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.N Engl J Med.2006; 354(6): 567–578.
54.
SartorC.I.. Mechanisms of disease: radiosensitization by epidermal growth factor receptor inhibitors.Nat Clin Pract Oncol.2004; 1(2): 80–87.
55.
KortmanskyJ.S., O'ReillyE.M., MinskyB.D.. A phase I trial of erlotinib, gemcitabine and radiation for patients with locally-advanced, unresectable pancreatic cancer.J Clin Oncol. 2005 ASCO Annual Meeting Proceedings.2005; 23(16s, Part I of II June 1 Suppl): 4107. Abstract.
56.
IannittiD., DipetrilloT., AkermanP.. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study.Am J Clin Oncol.2005; 28(6): 570–575.
57.
KrempienR., MuenterM.W., HuberP.E.. Randomized phase II: study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer. PARC: study protocol [ISRCTN56652283].BMC Cancer.2005; 5: 131.
58.
de GramontA., Van CutsemE.. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.Oncology.2005; 69(suppl 3): 46–56. Epub 2005 Nov 21.
59.
DingsR.P., LorenM., HeunH.. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization.Clin Cancer Res.2007; 13(11): 3395–3402.
60.
WillettC.G., BoucherY., di TomasoE.. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.Nat Med.2004; 10(2): 145–147. Epub 2004 Jan 25.
61.
CraneC.H., EllisL.M., AbbruzzeseJ.L.. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.J Clin Oncol.2006; 24(7): 1145–1151.
62.
SenzerN., ManiS., RosemurgyA.. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.J Clin Oncol.2004; 22(4): 592–601. Epub 2004 Jan 15.
63.
PosnerM., ChangK.J., RosemurgyA.. Multicenter phase II/III randomized controlled clinical trial using TNFerade combined with chemoradiation in patients with locally advanced pancreatic cancer (LAPC).J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part I.2007; 25(18s June 20 suppl): 4518. Abstract.
